Early results from implementation of HIV PrEP with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025
Despite remarkable advances in HIV prevention, more than 100,000 new diagnoses continue to be reported annually in the World Health Organization European Region. Between December 2024 and August 2025, two Italian centres specialising in HIV/sexually transmitted infection care offered long-acting injectable cabotegravir (CAB-LA) for pre-exposure prophylaxis (PrEP) in 265 individuals. CAB-LA was recently recommended in European guidelines (2024), but no real-world European data outside clinical trials have been reported to date. The programme specifically prioritised people with vulnerabilities that could compromise the effectiveness of oral PrEP, including suboptimal adherence, relevant comorbidities, and structural or behavioural barriers.
A rapid communication, published in Eurosurveillance, presented the characteristics of enrolled participants, their reasons for accessing CAB-LA, and early outcomes related to adherence, tolerability, safety and treatment discontinuations.
Access the full rapid communication here /open access/.
Source : Eurosurveillance
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.